Abstract
Postmenopausal osteoporosis (PMO) puts women at risk for hip and vertebral fractures, which are associated with a significant increase in morbidity and mortality. While there are a number of potential therapeutic options for the treatment of PMO, bisphosphonates are the treatment of choice. Osteonecrosis of the jaws (ONJ) has been associated with bisphosphonate use predominantly in patients treated with high cumulative drug doses for advanced malignancies. There have been a limited number of ONJ cases in PMO patients, who receive much smaller doses of bisphosphonates.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
